MX2021010492A - Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral. - Google Patents

Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral.

Info

Publication number
MX2021010492A
MX2021010492A MX2021010492A MX2021010492A MX2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A
Authority
MX
Mexico
Prior art keywords
methods
fucosyl
lactose
increasing brain
brain functionality
Prior art date
Application number
MX2021010492A
Other languages
English (en)
Inventor
Perez Alejandro Barranco
Gonzalez Maria Ramirez
Rachael Buck
Hernandez Enrique Vazquez
Cabrera Ricardo Rueda
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46940437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2021010492A publication Critical patent/MX2021010492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen métodos para mejorar el aprendizaje y/o la memoria, mejorar la adquisición de la memoria, la retención y recuperación de la memoria induciendo una mayor potenciación a largo plazo en la sinapsis neuronal hipocámpica en los individuos. Los métodos incluyen la administración de 2-fucosil-lactosa a un individuo.
MX2021010492A 2012-09-14 2015-03-13 Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral. MX2021010492A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12382356.9A EP2708147B1 (en) 2012-09-14 2012-09-14 Methods for increasing brain functionality using 2-fucosyl-lactose

Publications (1)

Publication Number Publication Date
MX2021010492A true MX2021010492A (es) 2021-10-01

Family

ID=46940437

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003425A MX2015003425A (es) 2012-09-14 2013-09-12 Metodos para aumentar la funcionalidad cerebral al usar 2-fucosil-lactosa.
MX2021010492A MX2021010492A (es) 2012-09-14 2015-03-13 Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003425A MX2015003425A (es) 2012-09-14 2013-09-12 Metodos para aumentar la funcionalidad cerebral al usar 2-fucosil-lactosa.

Country Status (13)

Country Link
US (1) US10398715B2 (es)
EP (2) EP2708147B1 (es)
CN (1) CN104780785A (es)
BR (1) BR112015005794A2 (es)
CA (1) CA2884634A1 (es)
DK (1) DK2708147T3 (es)
ES (1) ES2795665T3 (es)
IL (1) IL237617A0 (es)
MX (2) MX2015003425A (es)
MY (1) MY180148A (es)
PH (1) PH12015500546A1 (es)
SG (1) SG11201501893XA (es)
WO (1) WO2014043368A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
RU2706963C2 (ru) * 2014-11-26 2019-11-21 Абботт Лаборэтриз Молочная смесь, содержащая олигосахариды грудного молока, полиненасыщенные жирные кислоты, нуклеотиды и лютеин
MX2017006701A (es) * 2014-11-26 2018-02-13 Abbott Lab Fórmula infantil con rrr-alfa-tocoferol,2'-fucosilactosa y un probiótico.
US10835545B2 (en) 2015-10-28 2020-11-17 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
EP3368047B1 (en) 2015-10-28 2023-04-26 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
KR101731263B1 (ko) * 2016-04-25 2017-05-02 서울대학교 산학협력단 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법
WO2017215722A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic composition comprising hmo and method for modulating emotion and mood disorders
RU2019105567A (ru) 2016-07-28 2020-08-28 Фонтерра Ко-Оперэйтив Груп Лимитед Молочный продукт и способ
CN110573030A (zh) * 2017-05-24 2019-12-13 雀巢产品有限公司 用于增强注意力和/或降低冲动的营养组合物
WO2018215573A1 (en) * 2017-05-24 2018-11-29 Nestec S.A. Composition comprising oligofructose (of) for use in the improvement of short term memory and other cognitive benefits
MX2019011445A (es) 2017-05-24 2019-11-18 Nestle Sa Composicion que comprende oligosacaridos de la leche humana (hmo) para usar en la mejora de la memoria a corto plazo y otros beneficios cognitivos.
KR101953375B1 (ko) * 2017-11-20 2019-02-28 고려대학교 산학협력단 다양하고 신규한 퓨코실 올리고당의 제조법 및 이의 용도
KR20190130720A (ko) * 2018-05-15 2019-11-25 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물
WO2020178774A1 (en) * 2019-03-05 2020-09-10 Glycom A/S Human milk oligosaccharides for use in enhancing executive function
US20230414640A1 (en) 2020-12-04 2023-12-28 Societe Des Produits Nestle S.A. Stable aqueous composition for preterm to promote early postnal growth
CN114223723A (zh) * 2021-12-13 2022-03-25 黑龙江飞鹤乳业有限公司 营养组合物、包含其的食品以及该营养组合物的用途
KR102570073B1 (ko) * 2022-11-17 2023-08-24 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU694181B2 (en) * 1994-03-09 1998-07-16 Abbott Laboratories Humanized milk
KR970706271A (ko) 1994-09-20 1997-11-03 스티븐슨 린다 에스. 시냅스 전달 향상용 약제(drugs to improve synaptic transmission)
RU2199317C2 (ru) 1997-02-21 2003-02-27 Абботт Лаборэтриз Способ снижения заболеваемости некротическим энтероколитом у детей (варианты)
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
US20110104716A1 (en) * 2003-08-08 2011-05-05 Hasan Mohejeri Novel method for screening brain-active compounds
WO2008011538A2 (en) 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
MX2011004142A (es) 2008-11-03 2011-05-25 Nestec Sa Una composicion nutricional que comprende probioticos y que mejora los patrones de sueño.
CN102459295A (zh) * 2009-04-07 2012-05-16 格礼卡姆股份公司 2’-o-岩藻糖基乳糖的合成
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
CA2822660C (en) * 2010-12-31 2021-09-07 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides
MX352040B (es) * 2010-12-31 2017-11-07 Abbott Lab Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
WO2012092156A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
CN103379908B (zh) 2010-12-31 2020-02-14 雅培制药有限公司 使用人乳寡糖、维生素c和抗炎剂减少氧化应激的发病率的方法
EP3338784B1 (en) * 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
EP3335576A1 (en) * 2010-12-31 2018-06-20 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
ES2601891T3 (es) 2011-10-18 2017-02-16 Nestec S.A. Composición para su uso en crecimiento cerebral y/o desarrollo cognitivo y/o psicomotor
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico

Also Published As

Publication number Publication date
CN104780785A (zh) 2015-07-15
DK2708147T3 (da) 2020-05-18
CA2884634A1 (en) 2014-03-20
SG11201501893XA (en) 2015-04-29
US10398715B2 (en) 2019-09-03
EP2708147B1 (en) 2020-03-11
MY180148A (en) 2020-11-23
ES2795665T3 (es) 2020-11-24
BR112015005794A2 (pt) 2017-07-04
IL237617A0 (en) 2015-04-30
EP2708147A1 (en) 2014-03-19
WO2014043368A1 (en) 2014-03-20
MX2015003425A (es) 2015-06-22
US20150231159A1 (en) 2015-08-20
PH12015500546A1 (en) 2015-05-11
EP3704957A1 (en) 2020-09-09
EP2708147A8 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
PH12015500546A1 (en) Methods for increasing brain functionality using 2-fucosyl-lactose
HK1250620A1 (zh) 假體瓣膜、框架和小葉及其方法
HK1249002B (zh) 改進的具有小葉支架的假體心臟瓣膜
HK1215149A1 (zh) 人工心瓣葉片中的平面區域
EP3010448A4 (en) Prosthetic heart valve with linking element and methods for implanting same
ZA201500887B (en) Human anti-cd27 antibodies, methods and uses
MX2021001879A (es) Combinaciones de dosificaciones para reducir las respuestas inmunes humorales no deseadas.
CA139448S (en) Stimulation device
HK1170901A2 (en) A smart adjustable human body model
IL242224B (en) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
SG11201508115TA (en) Rewriteable aberration-corrected gradient-index intraocular lenses
EP3230439A4 (en) Human blood brain barrier model
EP2818135A4 (en) PIN TO SUPPORT DENTAL PROSTHESIS AND METHOD FOR THE MANUFACTURE THEREOF
EP2901848A4 (en) MASSIVE FIBER BODY AND ARTIFICIAL EARTH OF SOLID FIBER BODY
EP3191172A4 (en) Nerve cuff electrode for neuromodulation in large human nerve trunks
CA152179S (en) Analytical apparatus for drug testing
HUE050729T2 (hu) Fogászati implantátum, felépítmény, implantátum rendszer és implantációs készlet
EP3005981A4 (en) IMPLANTABLE LENS FOR MYOPIA AND METHOD FOR PREPARING SAID LENS
IL245086A0 (en) Retaining matrix system and dental implant
WO2014179771A8 (en) Dosing combinations for reducing undesired humoral immune responses
EP2865666A4 (en) HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE
WO2014135878A3 (en) Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency
EP2952160A4 (en) ORGANIC LIGHT TREATMENT SYSTEM, AND ENDOPROTHESIS
DK3011760T3 (da) Mellemøretransducer med biokompatibel implanterbar klæbepude
AU2013904589A0 (en) System and method for the capture and representation of the logic, structure, pattern and emotion of daily interactions as a habit, sequence or a regular course of procedure in the daily routine of people with disabilities